Efficacy and Safety of Enoxaparin in Hospitalized Patients with Severe Renal Insufficiency
A study evaluating the effect of thromboprophylaxis with enoxaparin at a dose of 20 mg/day in adult patients with renal failure compared the incidence of venous thromboembolism (VTE) with published results in patients without renal insufficiency who were prophylactically treated with enoxaparin at a dose of 40 mg/day. The authors also focused on the incidence of bleeding.
Evaluated Patient Population and Study Aims
This retrospective cohort study included adult patients with current creatinine clearance (CLcr) < 30 ml/min, who were treated outside the surgical department and were prescribed subcutaneous enoxaparin for at least 3 days. These were patients undergoing deep vein thrombosis (DVT) prophylaxis according to ACCP recommendations. Other primary monitored parameters were the incidence of VTE (DVT or pulmonary embolism/PE) and bleeding (both mild and significant) during hospitalization.
A total of 160 patients with an average age of 77 were evaluated, 62% of whom were men. Their average body weight was 71 kg, 23% had CLcr < 15 ml/min, and 34% were on hemodialysis. The majority (79%) of patients were admitted to the internal medicine department, 21% to the intensive care unit. The average length of hospitalization was 10 days. Reasons for thromboprophylaxis were immobilization (97.5%), VTE/PE history (3.1%), myocardial infarction/stroke/congestive heart failure (33.1%), rheumatic fever/infectious disease (31.9%), malignant disease or immunosuppressive therapy (6.9%), and age > 75 years (73.8%).
Results
VTE was detected in 9 (5.6%) patients during hospitalization, all cases being DVT. In multivariate analysis, a past occurrence of VTE was associated with an increased risk. Bleeding occurred in 37 (23.1%) patients, of which 16 (10%) were serious (requiring transfusion or a hemoglobin drop of ≥ 20 g/l). A higher risk of bleeding was found in patients older than 75 years, while it was lower in patients with CLcr 15–29 ml/min.
Conclusion
In patients with renal insufficiency hospitalized in the internal medicine department or ICU who require thromboprophylaxis, administration of enoxaparin at a dose of 20 mg/day s.c. is associated with a VTE incidence of 5.6%, which corresponds to the results published in patients with normal renal function treated with enoxaparin at a dose of 40 mg/day s.c. The incidence of major bleeding with this treatment was 10%.
(zza)
Source: Karaoui L. R., Tawil S., Salameh P., Chamoun N. Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. J Int Med Res 2019; 47 (1): 225−234, doi: 10.1177/0300060518799896.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
